PMID- 30589484
OWN - NLM
STAT- MEDLINE
DCOM- 20190730
LR  - 20190730
IS  - 1475-097X (Electronic)
IS  - 1475-0961 (Linking)
VI  - 39
IP  - 3
DP  - 2019 May
TI  - Factors determining exercise capacity evaluated during cardiopulmonary exercise 
      testing in 6-month follow-up after ST elevation myocardial infarction.
PG  - 209-214
LID - 10.1111/cpf.12560 [doi]
AB  - INTRODUCTION: ST elevation myocardial infarction (STEMI) is one of the main 
      causes of congestive heart failure (CHF). The main symptom of CHF is exercise 
      tolerance impairment. The aim of the study was to evaluate the prevalence and 
      risk factors for impaired exercise tolerance in patients after STEMI. METHODS AND 
      RESULTS: A total of 84 patients with STEMI were analysed in the study. 
      Cardiopulmonary exercise test (CPET) was performed 6 months after STEMI. Impaired 
      exercise tolerance defined as peak VO2 < 84% predicted for age and sex was 
      present in 49 (58%) patients and was connected with lack of abciximab 
      administration (91.4 versus 69%, P = 0.02) and the presence of mitral 
      regurgitation (47 versus 23%, P = 0.02). In univariate analysis, the troponin I 
      level at admission (OR 1.89, P = 0.047), the use of abciximab (OR 0.21, 
      P = 0.03), the presence of mitral regurgitation (OR 2.98, P = 0.03) and NT-proBNP 
      concentration (OR 2.17, P = 0.021) were related to impaired exercise tolerance. 
      The best multivariate model for predicting impaired exercise tolerance included 
      mitral regurgitation and lack of abciximab administration. CONCLUSIONS: Impaired 
      exercise tolerance after STEMI is common. Mitral regurgitation and lack of 
      abciximab administration are the best predicting factors of impaired exercise 
      tolerance after STEMI.
CI  - (c) 2019 Scandinavian Society of Clinical Physiology and Nuclear Medicine. 
      Published by John Wiley & Sons Ltd.
FAU - Turski, Maciej
AU  - Turski M
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
AD  - Department of Outpatient Cardiac Rehabilitation, Upper Silesian Medical Center, 
      Medical University of Silesia, Katowice, Poland.
FAU - Kocierz-Woznowska, Magdalena
AU  - Kocierz-Woznowska M
AUID- ORCID: 0000-0001-9073-4638
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
AD  - Department of Outpatient Cardiac Rehabilitation, Upper Silesian Medical Center, 
      Medical University of Silesia, Katowice, Poland.
FAU - Wybraniec, Maciej
AU  - Wybraniec M
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
FAU - Grabka, Marek
AU  - Grabka M
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
FAU - Wita, Marcin
AU  - Wita M
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
FAU - Berger-Kucza, Adrianna
AU  - Berger-Kucza A
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
FAU - Wita, Krystian
AU  - Wita K
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
FAU - Mizia-Stec, Katarzyna
AU  - Mizia-Stec K
AD  - 1st Department of Cardiology, Upper Silesian Medical Center, Medical University 
      of Silesia, Katowice, Poland.
LA  - eng
PT  - Journal Article
DEP - 20190117
PL  - England
TA  - Clin Physiol Funct Imaging
JT  - Clinical physiology and functional imaging
JID - 101137604
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - X85G7936GV (Abciximab)
MH  - Abciximab/therapeutic use
MH  - Aged
MH  - *Cardiorespiratory Fitness
MH  - *Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Failure/*diagnosis/epidemiology/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/*diagnosis/epidemiology/physiopathology
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Poland/epidemiology
MH  - Predictive Value of Tests
MH  - Prevalence
MH  - ST Elevation Myocardial Infarction/diagnosis/epidemiology/physiopathology/surgery
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - NT-proBNP
OT  - abciximab
OT  - impaired exercise tolerance
OT  - mitral regurgitation
OT  - peak oxygen consumption (peak VO2)
EDAT- 2018/12/28 06:00
MHDA- 2019/07/31 06:00
CRDT- 2018/12/28 06:00
PHST- 2017/10/24 00:00 [received]
PHST- 2018/12/17 00:00 [accepted]
PHST- 2018/12/28 06:00 [pubmed]
PHST- 2019/07/31 06:00 [medline]
PHST- 2018/12/28 06:00 [entrez]
AID - 10.1111/cpf.12560 [doi]
PST - ppublish
SO  - Clin Physiol Funct Imaging. 2019 May;39(3):209-214. doi: 10.1111/cpf.12560. Epub 
      2019 Jan 17.